187 related articles for article (PubMed ID: 23911227)
21. Characterization of PI3KCA and BRAF mutations in gastric adenocarcinoma: An approach to a personalized targeted therapy for Moroccan HER2 overexpressed patients.
Joutei HAH; Marchoudi N; Mahfoud W; Sadaoui I; Fechtali T; Benomar H
Arab J Gastroenterol; 2018 Dec; 19(4):155-158. PubMed ID: 30503528
[TBL] [Abstract][Full Text] [Related]
22. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
23. Oncogene alterations in endometrial carcinosarcomas.
Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
[TBL] [Abstract][Full Text] [Related]
24. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
[TBL] [Abstract][Full Text] [Related]
25. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care.
Roukos DH
Expert Rev Mol Diagn; 2010 Jan; 10(1):33-48. PubMed ID: 20014921
[TBL] [Abstract][Full Text] [Related]
26. HER2 amplification in gastric cancer is a rare event restricted to the intestinal phenotype.
Cruz-Reyes C; Gamboa-Dominguez A
Int J Surg Pathol; 2013 Jun; 21(3):240-6. PubMed ID: 23564704
[TBL] [Abstract][Full Text] [Related]
27. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
28. Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges.
Alameddine RS; Otrock ZK; Awada A; Shamseddine A
Curr Opin Oncol; 2013 May; 25(3):313-24. PubMed ID: 23518595
[TBL] [Abstract][Full Text] [Related]
29. Molecular pathology of gastric carcinoma.
Jang BG; Kim WH
Pathobiology; 2011; 78(6):302-10. PubMed ID: 22104201
[TBL] [Abstract][Full Text] [Related]
30. Translating gastric cancer genomics into targeted therapies.
Ang YL; Yong WP; Tan P
Crit Rev Oncol Hematol; 2016 Apr; 100():141-6. PubMed ID: 26947813
[TBL] [Abstract][Full Text] [Related]
31. Molecularly targeted therapies in advanced gastric cancer.
Janjigian YY; Shah MA
Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
Rosell R; Taron M; Reguart N; Isla D; Moran T
Clin Cancer Res; 2006 Dec; 12(24):7222-31. PubMed ID: 17189393
[TBL] [Abstract][Full Text] [Related]
33. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
34. The journey toward personalized cancer therapy.
Tulbah A; Chaudhri N; Al Dayel F; Akhtar M
Adv Anat Pathol; 2014 Jan; 21(1):36-43. PubMed ID: 24316909
[TBL] [Abstract][Full Text] [Related]
35. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK.
Rothschild SI
Cancers (Basel); 2015 May; 7(2):930-49. PubMed ID: 26018876
[TBL] [Abstract][Full Text] [Related]
36. [Immunohistochemistry and personalised medicine in lung oncology: advantages and limitations].
Hofman V; Ilie M; Long E; Lassalle S; Butori C; Bence C; Washetine K; Lalvee S; Hofman P
Bull Cancer; 2014 Oct; 101(10):958-65. PubMed ID: 25373695
[TBL] [Abstract][Full Text] [Related]
37. Advances in targeted therapy for gastric cancer based on tumor driver genes.
Wu S; Xu P; Zhang F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 53(1):73-83. PubMed ID: 38413217
[TBL] [Abstract][Full Text] [Related]
38. [Molecular Subtypes of Gastric Cancer].
Hatogai K; Doi T
Gan To Kagaku Ryoho; 2016 Mar; 43(3):281-5. PubMed ID: 27067842
[TBL] [Abstract][Full Text] [Related]
39. Emergence of
Subramanian J; Katta A; Masood A; Vudem DR; Kancha RK
Oncologist; 2019 Dec; 24(12):e1303-e1314. PubMed ID: 31292270
[TBL] [Abstract][Full Text] [Related]
40. Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach.
Lee J; Tran P; Klempner SJ
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e35-44. PubMed ID: 26880063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]